Biogen (BIIB) Non-Current Deferred Tax Liability (2009 - 2026)

Biogen's Non-Current Deferred Tax Liability history runs 18 years deep, the most recent figure standing at $945.5 million for Q2 2026.

• In Q2 2026, Non-Current Deferred Tax Liability rose 699.24% year-over-year to $945.5 million; the TTM figure through Jun 2026 stood at $945.5 million (up 699.24% YoY), while the FY2025 annual figure was $507.6 million, up 166.46% from the prior year.
• Non-Current Deferred Tax Liability for Q2 2026 stood at $945.5 million, up from $483.5 million in the prior quarter.
• The five-year high for Non-Current Deferred Tax Liability was $945.5 million in Q2 2026, with the low at $118.3 million in Q2 2025.
• The 5-year median for Non-Current Deferred Tax Liability is $482.0 million (2022), against an average of $463.8 million.
• The sharpest annual moves came in 2025 and 2026: Non-Current Deferred Tax Liability tumbled 79.97% in 2025, then surged 699.24% in 2026.
• Biogen's Non-Current Deferred Tax Liability stood at $334.7 million in 2022, then surged by 91.75% to $641.8 million in 2023, then plunged by 70.32% to $190.5 million in 2024, then jumped by 166.46% to $507.6 million in 2025, then soared by 86.27% to $945.5 million in 2026.
• Business Quant data shows BIIB's Non-Current Deferred Tax Liability at $945.5 million in Q2 2026, $483.5 million in Q1 2026, and $507.6 million in Q4 2025.